ClinicalTrials.gg
CompletedNCT01142726Updated Jan 14, 2016Results posted

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

A Phase 3 interventional study of Abatacept and Methotrexate in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 73 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-14.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
12th of 63
511 · median 119
Started
2010
with 1 other
Phase 3
26 of 63
2 open now
Registered
24th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 12th largest by enrollment, is one of 2 that started in 2010, is one of 26 in phase 3, and was the 24th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission following 6 months of drug withdrawal.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Presence of active clinical synovitis in at least 2 joints, 1 of which must have been a small joint, for a minimum of 8 weeks prior to screening
  • Onset of persistent symptoms ≤ 2 years prior to screening
  • Positive test result for anticyclic citrullinated peptides 2
  • Methotrexate naive or with minimum exposure to methotrexate, defined as no more than 10 mg/week for ≤4 weeks and no methotrexate dose for 1 month prior to screening visit
  • Biologic naive, including no treatment with an biologic prior to screening
  • Disease Activity Score 28 based on C-reactive protein score ≥3.2 at screening
  • Withdrawal from any treatment with chloroquine, hydroxychloroquine, and/or sulfasalazine (wash-out) for a minimum of 28 days prior to randomization
  • If receiving oral , on a stable low dose (≤ 10 mg/day prednisone equivalent) for at least 4 weeks
  • Able to undergo magnetic resonance imaging

Key Exclusion Criteria:

  • Meeting diagnostic criteria for other rheumatic disease (eg, lupus erythematosus)
  • Treatment with an intravenous, intramuscular, or intraarticular corticosteroid within 4 weeks prior to randomization
  • Scheduled for or anticipating joint replacement surgery
  • Presence of concomitant illness likely to require systemic glucocorticosteroid therapy during the study, in the opinion of the investigator
  • History of in the last 5 years
  • Any serious bacterial infection within the last 3 months not treated or resolved with antibiotics, or any chronic or recurrent bacterial infection
  • At risk for tuberculosis
  • Evidence of active or latent bacterial or viral infection at the time of potential enrollment, including human immunodeficiency or herpes zoster virus or cytomegalovirus that resolved less than 2 months prior to enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
511 participants (actual)

Study arms

  • Active comparator
    Abatacept, 125 mg, plus methotrexate, 2.5 mg

    Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period

    Drug: Abatacept · Drug: Methotrexate

  • Active comparator
    Methotrexate, 2.5 mg, plus abatacept placebo

    Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period

    Drug: Methotrexate · Drug: Abatacept placebo

  • Active comparator
    Abatacept, 125 mg, plus methotrexate placebo

    Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period

    Drug: Abatacept · Drug: Methotrexate placebo

Interventions

  • Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months

    Also known as: Orencia, BMS 188667

  • Tablets, oral, 2.5 mg, once weekly, 12 months

    Also known as: Rheumatrex

  • DrugAbatacept placebo

    Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months

  • DrugMethotrexate placebo

    Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18

    DAS28-CRP remission defined as \<2.6; TP=treatment phase; WP=withdrawal phase. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

    Time frame: Randomization to Months 12 and 18

Secondary outcomes

  1. Percentage of Participants Who Received Monotherapy and Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18

    TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

    Time frame: Randomization to Months 12 and 18

  2. Percentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time - Intent to Treat Population

    TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

    Time frame: Randomization to Month 24

  3. Adjusted Mean Change From Baseline in Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) at Months 6, 12, and 18

    TP=treatment period; WP=withdrawal period. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

    Time frame: Baseline to Month 18

  4. Percentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) at Months 12 and 18

    TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity.

    Time frame: Randomization to Month 18

  5. Adjusted Mean Change From Baseline in Scores on Simplified Disease Activity Index (SDAI) Over Time

    TP=treatment period; WP=withdrawal period. The SDAI is the simple linear sum of 5 outcome parameters: swollen joint count (SJC) and tender joint count (TJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SJC is assessed and recorded at each visit, with no swelling=0, swelling=1 (higher score indicates greater swelling). TJC is assessed at each visit through identification of joints that are painful under pressure or to passive motion, with no tenderness=0, tenderness=1 (higher score indicates greater affection due to disease activity)..

    Time frame: Randomization to Month 18

  6. Percentage of Participants Achieving a Health Assessment Questionnaire (HAQ) Response Over Time

    HAQ response defined as a reduction of at least 0.3 units from baseline in score on the Health Assessment Questionnaire Disability Index (HAQ-DI), which assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.

    Time frame: Randomization to Month 24

  7. Adjusted Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Over Time

    The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.

    Time frame: Randomization to Month 18

  8. Adjusted Mean Change From Baseline at Months 6, 12, and 18 in Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores of Short Form-36 (SF-36)

    TP=treatment period; WP=withdrawal period. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life (QOL) and comprises 8 domains, including 4 physical (physical health, bodily pain, physical functioning and physical role limitations) and 4 mental (mental health, vitality, social functioning, and emotional role limitation) subscales. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QOL (0=Poorest Health; 100=Best Health). Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.

    Time frame: Randomization to Months 6, 12, and 18

  9. Adjusted Mean Change From Baseline Over Time in Findings on Magnetic Resonance Imaging (MRI)

    TP=treatment period; WP=withdrawal period. Change from Baseline=Postbaseline-baseline value. MRI was used to assess joint damage progression at Months 6, 12, and 18. If \>20% of joints with a missing score for a parameter (erosion, osteitis, and synovitis), the MRI score of each parameter was considered missing. If ≤20% of joints had a missing score for a parameter, the MRI score for that parameter from the missing joints was carried forward from the previous MRI assessment, or carried backward from the next MRI assessment, if missing score occurred at baseline. MRI total score ranged from 0 (best outcome) to 4 (worst outcome). A gadolinium-enhanced MRI of the dominant hand-wrist was performed on all randomized patients at 5 points. The hand/wrist assessed to have more synovitis was selected initially and used for all subsequent evaluations. The MRI examination was standardized to ensure sufficient image quality for the evaluation of radiographic progression of rheumatoid arthritis.

    Time frame: Randomization to Month 18

  10. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Related Adverse Events (AEs), and Discontinuations Due to AEs During the Treatment Period

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.

    Time frame: Day 1 to up to 56 days following the last dosing day (Day 365); all deaths during study period, including those that occurred >56 days after last dose in Treatment Period

  11. Adverse Events (AEs) of Interest During the Treatment Period

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. AEs of special interest are events potentially associated with the drug or disease under study.

    Time frame: Day 1 to 56 days following last dosing day (Day 365)

  12. Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality During Treatment Period

    Lower limit of normal (LLN); Upper limit of normal (ULN); Pretreatment (preRX). Criteria for marked abnormality: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.

    Time frame: Day 1 up to 56 days following the last dosing day in the Treatment Period (Day 365)

  13. Percentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time During Withdrawal Period- Treated Participants in Remission at Month 12

    WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.). Percentage= number of participants with remission divided by number of participants who were analyzed (all treated participants who were in remission at end of treatment period and entered the Withdrawal Period)

    Time frame: End of Treatment Period (Month 12) to End of Withdrawal Period (Month 24)

  14. Percentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) Over Time in Treatment Period and Withdrawal Period

    TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity. Percent=number with remission/number evaluated (ITT)

    Time frame: Randomization to Month 24

  15. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs) and Discontinuations Due to AEs During the Full Study (All Periods)

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Includes data up to last active dose date +56 days if the participant discontinued the Treatment Period or did not enter the Withdrawal Period, up to the day of discontinuation in the Withdrawal Period for participants discontinuing the Withdrawal Period without entering the Re-exposure Period (RP), up to Day 729 visit (Month 24) for participants who complete the Withdrawal Period, and up to 56 days post last active dose in Re-exposure Period for participants entering the Re-exposure Period.

    Time frame: Day 1 to 56 days post last dose in the study, up to Month 30

  16. Adverse Events (AEs) of Interest During the Withdrawal Period

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes events with an onset date on or after 57 days post last dosing day (active abatacept or active MTX whichever is the later) in the Treatment Period and up to end of Withdrawal Period. Treatment groups represent treatment received during the Treatment Period.

    Time frame: Last dose in TP + 57 days, up to Month 24

  17. Adverse Events (AEs) of Interest During the Re-exposure Period

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes data up to 56 days post the last dosing day (active abatacept or active MTX, whichever is the later) in the Re-exposure Period. Treatment groups represent Treatment received during Treatment Period.

    Time frame: First dose in Re-exposure period up to last dose of Re-exposure Period + 56 days

  18. Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Withdrawal Period

    LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase (GGT) (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.

    Time frame: Last dose in TP + 57 days, up to Month 24

  19. Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Re-exposure Period

    LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.

    Time frame: Start of re-exposure period to 56 days post last dose, up to Month 30

07

Results

Posted Oct 17, 2014

Participant flow

Treatment Phase: Day 1 Through Month 12
Participant flow — Treatment Phase: Day 1 Through Month 12
MilestoneAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Started119116116
Completed1039196
Not completed162520
Withdrew: Adverse event585
Withdrew: Withdrawal by subject493
Withdrew: Lost to follow-up121
Withdrew: Poor compliance/noncompliance100
Withdrew: Lack of efficacy5611
Withdrawal Phase: Months 12 up to 24
Participant flow — Withdrawal Phase: Months 12 up to 24
MilestoneAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Started846675
Completed141017
Not completed705658
Withdrew: Adverse event001
Withdrew: Withdrawal by subject112
Withdrew: Pregnancy101
Withdrew: Lost to follow-up200
Withdrew: No longer met study criteria100
Withdrew: Lack of efficacy655453
Withdrew: Non-specified011
Re-Exposure Phase: Months 24 up to 30
Participant flow — Re-Exposure Phase: Months 24 up to 30
MilestoneAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Started554843
Completed544640
Not completed123
Withdrew: Adverse event001
Withdrew: Withdrawal by subject111
Withdrew: Pregnancy001
Withdrew: Lack of efficacy010

Outcome measures

PrimaryPercentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18

DAS28-CRP remission defined as \<2.6; TP=treatment phase; WP=withdrawal phase. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

Time frame:
Randomization to Months 12 and 18
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18
Percentage of participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgMethotrexate, 2.5 mg, Plus Abatacept Placebo
Month 12 (TP Day 365) (n=115, 115)60.945.2
Both Months 12 & 18 (WP Day 169) (n=115, 115)14.87.8
Statistical analysis
  • Abatacept, 125 mg, Plus Methotrexate, 2.5 mg vs Methotrexate, 2.5 mg, Plus Abatacept Placebo · Regression, Logistic · p = 0.010 · Odds ratio (or): 2.01 · 95% CI 1.18 to 3.43At Month 12
  • Abatacept, 125 mg, Plus Methotrexate, 2.5 mg vs Methotrexate, 2.5 mg, Plus Abatacept Placebo · Regression, Logistic · p = 0.045 · Odds ratio (or): 2.51 · 95% CI 1.02 to 6.18At Months 12 and 18
SecondaryPercentage of Participants Who Received Monotherapy and Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18

TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

Time frame:
Randomization to Months 12 and 18
Reported as:
Number · Percentage of participants
Percentage of Participants Who Received Monotherapy and Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18
Percentage of participantsAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
At Month 12 (TP Day 365) (n=113, 115)42.5 (33.36 to 51.59)45.2 (36.12 to 54.31)
At both Months 12 &18 (WP Day 169) (n=113, 115)12.4 (6.31 to 18.46)7.8 (2.92 to 12.73)
Statistical analysis
  • Abatacept, 125 mg, Plus Methotrexate Placebo vs Methotrexate, 2.5 mg, Plus Abatacept Placebo · Odds ratio (or): 0.92 · 95% CI 0.55 to 1.57At Month 12
  • Abatacept, 125 mg, Plus Methotrexate Placebo vs Methotrexate, 2.5 mg, Plus Abatacept Placebo · Odds ratio (or): 2.04 · 95% CI 0.81 to 5.14At Months 12 and 18
SecondaryPercentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time - Intent to Treat Population

TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

Time frame:
Randomization to Month 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time - Intent to Treat Population
Percentage of participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
TP Day 2913.4 (7.32 to 19.57)8.6 (3.51 to 13.73)6.0 (1.70 to 10.37)
TP Day 5724.4 (16.66 to 32.08)11.2 (5.47 to 16.95)9.5 (4.15 to 14.81)
TP Day 8536.1 (27.50 to 44.77)21.6 (14.07 to 29.03)17.2 (10.37 to 24.12)
TP Day 11337.8 (29.10 to 46.53)29.3 (21.03 to 37.59)19.0 (11.83 to 26.10)
TP Day 14145.4 (36.43 to 54.32)29.3 (21.03 to 37.59)25.0 (17.12 to 32.88)
TP Day 16945.4 (36.43 to 54.32)32.8 (24.22 to 41.30)26.7 (18.67 to 34.78)
TP Day 19752.1 (43.13 to 61.08)36.2 (27.46 to 44.95)25.9 (17.89 to 33.83)
TP Day 22557.1 (48.25 to 66.03)40.5 (31.58 to 49.45)30.2 (21.82 to 38.53)
TP Day 25362.2 (53.47 to 70.90)37.9 (29.10 to 46.76)30.2 (21.82 to 38.53)
TP 28151.3 (42.28 to 60.24)42.2 (33.25 to 51.23)32.8 (24.22 to 41.30)
TP 30956.3 (47.39 to 65.21)37.9 (29.10 to 46.76)36.2 (27.46 to 44.95)
TP Day 33763.0 (54.35 to 71.70)43.1 (34.09 to 52.12)33.6 (25.02 to 42.22)
TP 36561.3 (52.60 to 70.09)43.1 (34.09 to 52.12)45.7 (36.62 to 54.75)
WP Day 2951.3 (42.28 to 60.24)36.2 (27.46 to 44.95)27.6 (19.45 to 35.72)
WP Day 5740.3 (31.52 to 49.15)25.0 (17.12 to 32.88)18.1 (11.10 to 25.11)
WP Day 8531.1 (22.78 to 39.41)18.1 (11.10 to 25.11)18.1 (11.10 to 25.11)
WP Day 16919.3 (12.23 to 26.42)12.9 (6.82 to 19.04)9.5 (4.15 to 14.81)
WP Day 25317.6 (10.80 to 24.50)9.5 (4.15 to 14.81)13.8 (7.52 to 20.07)
WP Day 3659.2 (4.04 to 14.45)6.0 (1.70 to 10.37)6.0 (1.70 to 10.37)
SecondaryAdjusted Mean Change From Baseline in Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) at Months 6, 12, and 18

TP=treatment period; WP=withdrawal period. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)

Time frame:
Baseline to Month 18
Reported as:
Mean · Units on a scale
Adjusted Mean Change From Baseline in Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) at Months 6, 12, and 18
Units on a scaleAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Month 6 (TP Day 169) (n=102, 96, 101)-2.72 ± 0.12-2.33 ± 0.12-1.93 ± 0.12
Month 12 (TP Day 365) (n=95, 84, 91)-3.09 ± 0.13-2.75 ± 0.13-2.58 ± 0.13
Month 18 (WP Day 169) (n=41, 31, 32)-1.54 ± 0.26-1.51 ± 0.29-1.06 ± 0.29
SecondaryPercentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) at Months 12 and 18

TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity.

Time frame:
Randomization to Month 18
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) at Months 12 and 18
Percentage of participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Month 12 (TP Day 365)42.0 (33.15 to 50.89)29.3 (21.03 to 37.59)25.0 (17.12 to 32.88)
Month 18 (WP Day 169)10.9 (5.32 to 16.53)8.6 (3.51 to 13.73)6.9 (2.29 to 11.51)
SecondaryAdjusted Mean Change From Baseline in Scores on Simplified Disease Activity Index (SDAI) Over Time

TP=treatment period; WP=withdrawal period. The SDAI is the simple linear sum of 5 outcome parameters: swollen joint count (SJC) and tender joint count (TJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SJC is assessed and recorded at each visit, with no swelling=0, swelling=1 (higher score indicates greater swelling). TJC is assessed at each visit through identification of joints that are painful under pressure or to passive motion, with no tenderness=0, tenderness=1 (higher score indicates greater affection due to disease activity)..

Time frame:
Randomization to Month 18
Reported as:
Mean · Units on a scale
Adjusted Mean Change From Baseline in Scores on Simplified Disease Activity Index (SDAI) Over Time
Units on a scaleAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
TP Day 29 (n=109, 101, 107)-13.11 ± 1.33-12.14 ± 1.37-10.12 ± 1.33
TP Day 57 (n=108, 101, 103)-18.90 ± 1.25-15.83 ± 1.28-15.99 ± 1.26
TP Day 85 (n=108, 99, 103)-24.13 ± 1.16-20.51 ± 1.20-19.55 ± 1.17
TP Day 113 (n=103, 98, 101)-25.47 ± 1.12-23.56 ± 1.15-21.02 ± 1.13
TP Day 141 (n=104, 96, 104)-27.15 ± 1.10-25.99 ± 1.13-22.14 ± 1.10
TP Day 169 (n=102, 96, 100)-28.42 ± 1.08-26.20 ± 1.11-22.80 ± 1.09
TP Day 197 (n=103, 97, 96)-29.66 ± 1.01-27.57 ± 1.03-24.37 ± 1.02
TP Day 225 (n=99, 94, 92)-30.13 ± 1.04-28.39 ± 1.06-24.73 ± 1.06
TP Day 253 (n=98, 94, 91)-31.14 ± 1.04-28.10 ± 1.06-25.80 ± 1.05
TP 281 (n=96, 93, 89)-30.98 ± 1.10-28.16 ± 1.12-26.23 ± 1.12
TP 309 (n=91, 87, 92)-30.82 ± 1.16-27.79 ± 1.18-26.36 ± 1.17
TP Day 337 (n=93, 84, 87)-31.11 ± 1.15-29.34 ± 1.19-27.26 ± 1.17
TP 365 (n=95, 84, 91)-31.24 ± 1.17-28.88 ± 1.21-28.34 ± 1.19
WP Day 29 (n=73, 59, 64)-30.42 ± 1.32-28.05 ± 1.39-23.52 ± 1.36
WP Day 57 (n=69, 54, 59)-27.68 ± 1.59-24.17 ± 1.74-17.94 ± 1.68
WP Day 85 (n=67, 47, 52)-22.00 ± 2.18-21.55 ± 2.57-17.54 ± 2.44
WP Day 169 (n=41, 31, 32)-17.43 ± 2.82-19.13 ± 3.25-13.64 ± 3.19
SecondaryPercentage of Participants Achieving a Health Assessment Questionnaire (HAQ) Response Over Time

HAQ response defined as a reduction of at least 0.3 units from baseline in score on the Health Assessment Questionnaire Disability Index (HAQ-DI), which assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.

Time frame:
Randomization to Month 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Health Assessment Questionnaire (HAQ) Response Over Time
Percentage of participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
TP Day 2942.0 (33.15 to 50.89)31.0 (22.62 to 39.45)21.6 (14.07 to 29.03)
TP Day 5755.5 (46.53 to 64.39)44.0 (34.93 to 53.00)37.9 (29.10 to 46.76)
TP Day 8563.0 (54.35 to 71.70)45.7 (36.62 to 54.75)41.4 (32.42 to 50.34)
TP Day 11363.0 (54.35 to 71.70)49.1 (40.04 to 58.24)45.7 (36.62 to 54.75)
TP Day 14162.2 (53.47 to 70.90)51.7 (42.63 to 60.82)44.0 (34.93 to 53.00)
TP Day 16963.9 (55.23 to 72.50)56.0 (47.00 to 65.07)41.4 (32.42 to 50.34)
TP Day 19766.4 (57.90 to 74.87)59.5 (50.55 to 68.42)41.4 (32.42 to 50.34)
TP Day 22566.4 (57.90 to 74.87)57.8 (48.77 to 66.75)38.8 (29.93 to 47.66)
TP Day 25368.9 (60.59 to 77.22)55.2 (46.12 to 64.22)45.7 (36.62 to 54.75)
TP Day 28164.7 (56.12 to 73.29)56.9 (47.88 to 65.91)46.6 (37.47 to 55.63)
TP Day 30965.5 (57.01 to 74.08)56.9 (47.88 to 65.91)46.6 (37.47 to 55.63)
TP Day 33764.7 (56.12 to 73.29)55.2 (46.12 to 64.22)46.6 (37.47 to 55.63)
TP Day 36567.2 (58.79 to 75.66)52.6 (43.50 to 61.67)44.0 (34.93 to 53.00)
WP Day 2952.1 (43.13 to 61.08)39.7 (30.75 to 48.56)37.1 (28.28 to 45.86)
WP Day 5743.7 (34.79 to 52.61)34.5 (25.83 to 43.13)26.7 (18.67 to 34.78)
WP Day 8539.5 (30.71 to 48.28)28.4 (20.24 to 36.66)23.3 (15.59 to 30.97)
WP Day 16922.7 (15.16 to 30.21)16.4 (9.64 to 23.11)10.3 (4.80 to 15.89)
WP Day 25315.1 (8.69 to 21.56)9.5 (4.15 to 14.81)6.9 (2.29 to 11.51)
WP Day 36510.1 (4.67 to 15.49)6.9 (2.29 to 11.51)5.2 (1.14 to 9.20)
SecondaryAdjusted Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Over Time

The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.

Time frame:
Randomization to Month 18
Reported as:
Mean · Units on a scale
Adjusted Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Over Time
Units on a scaleAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
TP Day 29 (n=104, 103, 91)-0.33 ± 0.05-0.21 ± 0.05-0.09 ± 0.05
TP Day 57 (n=102, 100, 93)-0.48 ± 0.05-0.38 ± 0.05-0.32 ± 0.05
TP Day 85 (n=105, 97, 88)-0.64 ± 0.05-0.45 ± 0.05-0.40 ± 0.05
TP Day 113 (n=105, 98, 90)-0.67 ± 0.05-0.55 ± 0.05-0.50 ± 0.05
TP Day 141 (n=100, 98, 88)-0.72 ± 0.05-0.53 ± 0.05-0.46 ± 0.06
TP Day 169 (n=95, 95, 85)-0.74 ± 0.05-0.59 ± 0.05-0.52 ± 0.06
TP Day 197 (n=99, 96, 83)-0.78 ± 0.05-0.62 ± 0.06-0.54 ± 0.06
TP Day 225 (n=98, 95, 83)-0.79 ± 0.06-0.67 ± 0.06-0.56 ± 0.06
TP Day 253 (n=96, 91, 84)-0.82 ± 0.05-0.65 ± 0.06-0.63 ± 0.06
TP Day 281 (n=90, 93, 81)-0.82 ± 0.06-0.65 ± 0.06-0.62 ± 0.06
TP Day 309 (n=89, 88, 82)-0.81 ± 0.06-0.67 ± 0.06-0.66 ± 0.06
TP Day 337 (n=88, 85, 80)-0.84 ± 0.06-0.70 ± 0.06-0.70 ± 0.06
TP Day 365 (n=90, 82, 77)-0.87 ± 0.06-0.73 ± 0.06-0.72 ± 0.06
WP Day 29 (n=70, 55, 55)-0.85 ± 0.06-0.67 ± 0.07-0.63 ± 0.07
WP Day 57 (n=66, 53, 54)-0.67 ± 0.07-0.58 ± 0.08-0.39 ± 0.08
WP Day 85 (n=65, 45, 46)-0.54 ± 0.08-0.48 ± 0.09-0.37 ± 0.09
WP Day 169 (n=34, 28, 26)-0.52 ± 0.10-0.49 ± 0.11-0.33 ± 0.12
SecondaryAdjusted Mean Change From Baseline at Months 6, 12, and 18 in Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores of Short Form-36 (SF-36)

TP=treatment period; WP=withdrawal period. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life (QOL) and comprises 8 domains, including 4 physical (physical health, bodily pain, physical functioning and physical role limitations) and 4 mental (mental health, vitality, social functioning, and emotional role limitation) subscales. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QOL (0=Poorest Health; 100=Best Health). Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.

Time frame:
Randomization to Months 6, 12, and 18
Reported as:
Mean · Units on a scale
Adjusted Mean Change From Baseline at Months 6, 12, and 18 in Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores of Short Form-36 (SF-36)
Units on a scaleAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
PCS score TP Day 169 (n=106, 95, 96)11.68 ± 0.829.16 ± 0.867.47 ± 0.85
PCS score TP Day 365 (n=94, 88, 91)13.91 ± 0.9310.23 ± 0.9710.92 ± 0.95
PCS score WP Day 169 (n=48, 36, 37)6.16 ± 1.454.59 ± 1.656.27 ± 1.63
MCS score TP Day 169 (n=106, 95, 96)6.11 ± 0.923.99 ± 0.974.69 ± 0.95
MCS score TP Day 365 (n=94, 88, 91)7.67 ± 1.045.48 ± 1.087.23 ± 1.06
MCS score WP Day 169 (n=48, 36, 37)2.75 ± 1.444.36 ± 1.642.23 ± 1.63
SecondaryAdjusted Mean Change From Baseline Over Time in Findings on Magnetic Resonance Imaging (MRI)

TP=treatment period; WP=withdrawal period. Change from Baseline=Postbaseline-baseline value. MRI was used to assess joint damage progression at Months 6, 12, and 18. If \>20% of joints with a missing score for a parameter (erosion, osteitis, and synovitis), the MRI score of each parameter was considered missing. If ≤20% of joints had a missing score for a parameter, the MRI score for that parameter from the missing joints was carried forward from the previous MRI assessment, or carried backward from the next MRI assessment, if missing score occurred at baseline. MRI total score ranged from 0 (best outcome) to 4 (worst outcome). A gadolinium-enhanced MRI of the dominant hand-wrist was performed on all randomized patients at 5 points. The hand/wrist assessed to have more synovitis was selected initially and used for all subsequent evaluations. The MRI examination was standardized to ensure sufficient image quality for the evaluation of radiographic progression of rheumatoid arthritis.

Time frame:
Randomization to Month 18
Reported as:
Mean · Units on a scale
Adjusted Mean Change From Baseline Over Time in Findings on Magnetic Resonance Imaging (MRI)
Units on a scaleAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Osteitis TP Day 169 (n=93, 94, 89)-2.03 ± 0.47-1.13 ± 0.47-0.73 ± 0.48
Osteitis TP Day 365 (n=83, 74, 78)-2.32 ± 0.46-1.30 ± 0.46-0.90 ± 0.46
Osteitis WP Day 169 (n=31, 30, 25)-1.94 ± 0.880.98 ± 0.89-0.33 ± 0.96
Erosion TP Day 169 (n=93, 94, 89)0.26 ± 0.281.15 ± 0.281.15 ± 0.28
Erosion TP Day 365 (n=83, 74, 78)0.34 ± 0.351.57 ± 0.361.56 ± 0.36
Erosion WP Day 169 (n=31, 30, 25)0.20 ± 0.472.16 ± 0.481.89 ± 0.50
Synovitis TP Day 169 (n=93, 94, 89)-1.82 ± 0.21-0.93 ± 0.21-0.78 ± 0.21
Synovitis TP Day 365 (n=83, 74, 78)-2.38 ± 0.29-1.36 ± 0.30-0.77 ± 0.30
Synovitis WP Day 169 (n=31, 30, 25))-1.71 ± 0.45-0.95 ± 0.45-0.71 ± 0.49
SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Related Adverse Events (AEs), and Discontinuations Due to AEs During the Treatment Period

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.

Time frame:
Day 1 to up to 56 days following the last dosing day (Day 365); all deaths during study period, including those that occurred >56 days after last dose in Treatment Period
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Related Adverse Events (AEs), and Discontinuations Due to AEs During the Treatment Period
ParticipantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Deaths002
SAEs8149
Related SAEs331
Discontinuations due to SAEs253
Related AEs534851
Discontinuations due to AEs485
SecondaryAdverse Events (AEs) of Interest During the Treatment Period

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. AEs of special interest are events potentially associated with the drug or disease under study.

Time frame:
Day 1 to 56 days following last dosing day (Day 365)
Reported as:
Number · Participants
Adverse Events (AEs) of Interest During the Treatment Period
ParticipantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Infections686469
Malignancy121
Autoimmune disorders (prespecified)123
Local injection site reactions (prespecified)200
SecondaryNumber of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality During Treatment Period

Lower limit of normal (LLN); Upper limit of normal (ULN); Pretreatment (preRX). Criteria for marked abnormality: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.

Time frame:
Day 1 up to 56 days following the last dosing day in the Treatment Period (Day 365)
Reported as:
Number · Participants
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality During Treatment Period
ParticipantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Platelet count (high) (n=119, 116, 115)200
Potassium, serum (low)111
Blood urea nitrogen (high)412
Creatinine (high)213
Alanine aminotransferase (ALT)(high)302
Aspartate aminotransferase (AST)(high)201
G-glutamyl transferase (GGT) (high)311
Glucose, fasting (low) (n=78, 72, 75)202
Glucose, fasting (high) (n=78, 72, 75)121
Glucose, serum (low) (n=84, 78, 75)562
Glucose, serum (high) (n=84, 78, 75)143
Uric acid (high)010
Albumin (low)114
Hemoglobin (low) (n=119, 116, 115)020
Hematocrit (low) (n=119, 116, 115)020
SecondaryPercentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time During Withdrawal Period- Treated Participants in Remission at Month 12

WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.). Percentage= number of participants with remission divided by number of participants who were analyzed (all treated participants who were in remission at end of treatment period and entered the Withdrawal Period)

Time frame:
End of Treatment Period (Month 12) to End of Withdrawal Period (Month 24)
Reported as:
Number · percentage of participants
Percentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time During Withdrawal Period- Treated Participants in Remission at Month 12
percentage of participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
WP Day 2973.3 (65.46 to 85.23)72.0 (59.55 to 84.45)54.7 (41.32 to 68.12)
WP Day 5758.9 (47.62 to 70.19)56.0 (42.24 to 69.76)32.1 (19.51 to 44.64)
WP Day 8542.5 (31.13 to 53.80)40.0 (26.42 to 53.58)35.8 (22.94 to 48.76)
WP Day 16926.0 (15.96 to 36.09)30.0 (17.30 to 42.70)17.0 (6.87 to 27.09)
WP Day 25320.5 (11.28 to 29.82)22.0 (10.52 to 33.48)20.8 (9.84 to 31.67)
WP Day 36512.3 (4.79 to 19.87)14.0 (4.38 to 23.62)11.3 (2.79 to 19.85)
SecondaryPercentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) Over Time in Treatment Period and Withdrawal Period

TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity. Percent=number with remission/number evaluated (ITT)

Time frame:
Randomization to Month 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) Over Time in Treatment Period and Withdrawal Period
percentage of participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
TP Day 294.2 (1.38 to 9.53)3.4 (0.95 to 8.59)1.7 (0.21 to 6.09)
TP Day 579.2 (4.71 to 15.94)6.0 (2.46 to 12.04)1.7 (0.21 to 6.09)
TP Day 8517.6 (10.80 to 24.50)8.6 (3.51 to 13.73)6.0 (1.70 to 10.37)
TP Day 11323.5 (15.91 to 31.15)17.2 (10.37 to 24.12)7.8 (2.89 to 12.63)
TP Day 14131.9 (23.56 to 40.31)23.3 (15.59 to 30.97)10.3 (4.80 to 15.89)
TP Day 16931.1 (22.78 to 39.41)20.7 (13.32 to 28.06)11.2 (5.47 to 16.95)
TP Day 19733.6 (25.13 to 42.10)21.6 (14.07 to 29.03)12.9 (6.82 to 19.04)
TP Day 22538.7 (29.91 to 47.40)25.9 (17.89 to 33.83)14.7 (8.22 to 21.09)
TP Day 25337.8 (29.10 to 46.53)25.0 (17.12 to 32.88)13.8 (7.52 to 20.07)
TP Day 28137.8 (29.10 to 46.53)26.7 (18.67 to 34.78)18.1 (11.10 to 25.11)
TP Day 30940.3 (31.52 to 49.15)26.7 (18.67 to 34.78)19.0 (11.83 to 26.10)
TP Day 33741.2 (32.33 to 50.02)31.0 (22.62 to 39.45)19.0 (11.83 to 26.10)
TP Day 36542.0 (33.15 to 50.89)29.3 (21.03 to 37.59)25.0 (17.12 to 32.88)
WP Day 2938.7 (29.91 to 47.40)26.7 (18.67 to 34.78)14.7 (8.22 to 21.09)
WP Day 5726.9 (18.92 to 34.86)20.7 (13.32 to 28.06)10.3 (4.80 to 15.89)
WP Day 8521.0 (13.69 to 28.33)15.5 (8.93 to 22.11)14.7 (8.22 to 21.09)
WP Day 16911.8 (5.98 to 17.55)9.5 (4.15 to 14.81)6.9 (2.29 to 11.51)
WP Day 25311.8 (5.98 to 17.55)9.5 (4.15 to 14.81)7.8 (2.89 to 12.63)
WP Day 3656.7 (2.22 to 11.22)4.3 (0.61 to 8.01)4.3 (0.61 to 8.01)
SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs) and Discontinuations Due to AEs During the Full Study (All Periods)

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Includes data up to last active dose date +56 days if the participant discontinued the Treatment Period or did not enter the Withdrawal Period, up to the day of discontinuation in the Withdrawal Period for participants discontinuing the Withdrawal Period without entering the Re-exposure Period (RP), up to Day 729 visit (Month 24) for participants who complete the Withdrawal Period, and up to 56 days post last active dose in Re-exposure Period for participants entering the Re-exposure Period.

Time frame:
Day 1 to 56 days post last dose in the study, up to Month 30
Reported as:
Number · participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs) and Discontinuations Due to AEs During the Full Study (All Periods)
participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Death002
SAE111515
Discontinued Due to AE487
SecondaryAdverse Events (AEs) of Interest During the Withdrawal Period

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes events with an onset date on or after 57 days post last dosing day (active abatacept or active MTX whichever is the later) in the Treatment Period and up to end of Withdrawal Period. Treatment groups represent treatment received during the Treatment Period.

Time frame:
Last dose in TP + 57 days, up to Month 24
Reported as:
Number · participants
Adverse Events (AEs) of Interest During the Withdrawal Period
participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Infections8610
Malignancy101
Autoimmune disorders (prespecified)001
Local injection site reactions(prespecified)000
SecondaryAdverse Events (AEs) of Interest During the Re-exposure Period

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes data up to 56 days post the last dosing day (active abatacept or active MTX, whichever is the later) in the Re-exposure Period. Treatment groups represent Treatment received during Treatment Period.

Time frame:
First dose in Re-exposure period up to last dose of Re-exposure Period + 56 days
Reported as:
Number · participants
Adverse Events (AEs) of Interest During the Re-exposure Period
participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Infections17812
Malignancy000
Autoimmune Disorders (prespecified)000
Local Injection site reactions (prespecified)000
SecondaryNumber of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Withdrawal Period

LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase (GGT) (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.

Time frame:
Last dose in TP + 57 days, up to Month 24
Reported as:
Number · participants
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Withdrawal Period
participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Hemoglobin Low (n=60, 52, 48)120
Creatinine High (n=60, 52, 48)122
Alanine aminotransferase (ALT) High (n=60, 52, 48)100
GGT High (n=60, 52, 48)100
Fasting Glucose High (30, 28, 25)021
Glucose Low (n=36,31,27)530
Glucose High (n=36, 31, 27)011
SecondaryNumber of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Re-exposure Period

LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.

Time frame:
Start of re-exposure period to 56 days post last dose, up to Month 30
Reported as:
Number · participants
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Re-exposure Period
participantsAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
Hematocrit Low (n=55,47,43)010
Hemoglobin Low (n=55,48, 43)020
Creatinine High (n=55, 48, 43)010
ALT High (n=55, 48, 43)202
ALP High (n=55, 48, 43)100
AST High (n=55, 48, 43)201
GGT High (n=55, 48, 43)201
Fasting Glucose Low (n=33, 32, 28)100
Fasting Glucose High (n=33, 32, 28)021
Glucose Low (n=27,24,18)020
Glucose High (n=27,24,18)000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept, 125 mg, Plus Methotrexate, 2.5 mg—11/119 (9.2%)81/119 (68.1%)
Abatacept, 125 mg, Plus Methotrexate Placebo—15/116 (12.9%)64/116 (55.2%)
Methotrexate, 2.5 mg, Plus Abatacept Placebo—15/116 (12.9%)78/116 (67.2%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
OverdoseInjury, poisoning and procedural complications3/1191/1162/116
Carotid artery occlusionNervous system disorders0/1191/1160/116
CholelithiasisHepatobiliary disorders0/1190/1161/116
Endometrial disorderReproductive system and breast disorders0/1191/1160/116
Small intestinal obstructionGastrointestinal disorders0/1190/1161/116
Urinary tract infectionInfections and infestations0/1190/1161/116
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1190/1161/116
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1190/1161/116
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1191/1160/116
DepressionPsychiatric disorders0/1191/1160/116
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAbatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept Placebo
NasopharyngitisInfections and infestations28/11920/11622/116
Upper respiratory tract infectionInfections and infestations15/11915/11620/116
NauseaGastrointestinal disorders18/1198/11616/116
Urinary tract infectionInfections and infestations14/11915/11615/116
BronchitisInfections and infestations8/1196/11610/116
CoughRespiratory, thoracic and mediastinal disorders4/1199/1167/116
InfluenzaInfections and infestations5/1199/1166/116
SinusitisInfections and infestations9/1194/1162/116
HeadacheNervous system disorders8/1198/1167/116
DiarrhoeaGastrointestinal disorders5/1198/1164/116

Baseline characteristics

All randomized patients who received at least 1 dose of double-blind study medication in the Treatment Period

Age, Continuous
Age, Continuous(Years)Abatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept PlaceboTotal
Mean46.4 ± 13.2045.4 ± 11.9249.1 ± 12.3647.0 ± 12.57
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept PlaceboTotal
Female958989273
Male24272778
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept PlaceboTotal
White10095102297
Asian1413936
Black/African American2428
American Indian/Alaska native1113
Other2327
Duration of rheumatoid arthritis
Duration of rheumatoid arthritis(Years)Abatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept PlaceboTotal
Mean0.58 ± 0.5000.59 ± 0.5220.50 ± 0.4880.56 ± 0.504
Disease Activity Score 28 based on C-reactive protein (DAS28-CRP)
Disease Activity Score 28 based on C-reactive protein (DAS28-CRP)(Units on a scale)Abatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept PlaceboTotal
Mean5.528 ± 1.25015.463 ± 1.14935.315 ± 1.33305.435 ± 1.2465
Health Assessment Questionnaire Disability Index (HAQ-DI) score
Health Assessment Questionnaire Disability Index (HAQ-DI) score(Units on a scale)Abatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept PlaceboTotal
Mean1.452 ± 0.67781.419 ± 0.65871.383 ± 0.64931.419 ± 0.6609
Rheumatoid factor status
Rheumatoid factor status(Participants)Abatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept PlaceboTotal
Positive113111110334
Negative65617
Tender joint count
Tender joint count(Joints)Abatacept, 125 mg, Plus Methotrexate, 2.5 mgAbatacept, 125 mg, Plus Methotrexate PlaceboMethotrexate, 2.5 mg, Plus Abatacept PlaceboTotal
Mean24.3 ± 15.7423.9 ± 14.4721.7 ± 14.0023.3 ± 14.77

1 further baseline measures are reported on the registry.

08

Study locations

73 sites
  • Rheumatology Associates Of North Alabama, P.C.
    Huntsville, Alabama 35801, United States
  • St. Joseph'S Mercy Clinic
    Hot Springs, Arkansas 71913, United States
  • Sarasota Arthritis Research Center
    Sarasota, Florida 34239, United States
  • Coeur D'Alene Arthrit Clin
    Coeur D Alene, Idaho 83814, United States
  • Johns Hopkins University Division Of Rheumatology
    Baltimore, Maryland 21224, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Arthritis Associates Of Mississippi
    Jackson, Mississippi 39202, United States
  • Physician Research Collaboration, Llc
    Lincoln, Nebraska 68516, United States
  • Piedmont Rheumatology, Pa
    Hickory, North Carolina 28602, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • Metrohealth Medical Center
    Cleveland, Ohio 44109, United States
  • Isam A. Diab, Md
    Middleburg, Ohio 44130, United States
  • Alan J. Kivitz, Md, Cpi
    Duncansville, Pennsylvania 16635, United States
  • Mitchell C. Feinman, Md
    Orangeburg, South Carolina 29118, United States
  • Kurt Oelke, Md
    Glendale, Wisconsin 53217, United States
  • Local Institution
    Cairns, Queensland 4870, Australia
  • Local Institution
    Maroochydore, Queensland 4558, Australia
  • Local Institution
    Woodville, South Australia 5011, Australia
  • Local Institution
    Heidelberg, Victoria 3084, Australia
  • Local Institution
    Malvern, Victoria 3144, Australia
  • Local Institution
    Victoria Park, Western Australia 6100, Australia
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Kortrijk, 8500, Belgium
  • Local Institution
    Merksem, 2170, Belgium
  • Local Institution
    Calgary, Alberta T2N 4N1, Canada
  • Local Institution
    Laval, Quebec H7T 2P5, Canada
  • Local Institution
    Hjorring, 9800, Denmark
  • Local Institution
    Helsinki, 00290, Finland
  • Local Institution
    Tampere, 33521, Finland
  • Local Institution
    Chambray Les Tours, 37170, France
  • Local Institution
    Montpellier, 34295, France
  • Local Institution
    Paris Cedex 14, 75679, France
  • Local Institution
    Poitiers, 86021, France
  • Local Institution
    Berlin, 10117, Germany
  • Local Institution
    Berlin, 14059, Germany
  • Local Institution
    Hildesheim, 31134, Germany
  • Local Institution
    Muenchen, 80336, Germany
  • Local Institution
    Muenchen, 80639, Germany
  • Local Institution
    Muenchen, 81541, Germany
  • Local Institution
    Ancona, 60055, Italy
  • Local Institution
    Siena, 53100, Italy
  • Local Institution
    Daegu, 705-718, Korea, Republic of
  • Local Institution
    Daejeon, 302-799, Korea, Republic of
  • Local Institution
    Seoul, 133-791, Korea, Republic of
  • Local Institution
    Seoul, 137-701, Korea, Republic of
  • Local Institution
    Metepec, Estado De Mexico 52140, Mexico
  • Local Institution
    Guadalajara, Jalisco 44500, Mexico
  • Local Institution
    Guadalajara, Jalisco 44690, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64020, Mexico
  • Local Institution
    Merida, Yucatan 97000, Mexico
  • Local Institution
    Chihuahua, 31000, Mexico
  • Local Institution
    Queretaro, 76178, Mexico
  • Local Institution
    San Luis Potosi, 78240, Mexico
  • Local Institution
    Lublin, 20-954, Poland
  • Local Institution
    Poznan, 60-218, Poland
  • Local Institution
    Torun, 87100, Poland
  • Local Institution
    Warszawa, 01-157, Poland
  • Local Institution
    Warszawa, 01-868, Poland
  • Local Institution
    Wroc#aw, 50-088, Poland
  • Local Institution
    Moscow, 117049, Russian Federation
  • Local Institution
    Moscow, 129327, Russian Federation
  • Local Institution
    Tver, 170036, Russian Federation
  • Local Institution
    Kempton Park, Gauteng 1619, South Africa
  • Local Institution
    Pretoria, Gauteng 0083, South Africa
  • Local Institution
    Pretoria, Gauteng 0084, South Africa
  • Local Institution
    Pretoria, Gauteng 0181, South Africa
  • Local Institution
    Durban, Kwa Zulu Natal 4001, South Africa
  • Local Institution
    Panorama, Western Cape 7500, South Africa
  • Local Institution
    Goteborg, 413 45, Sweden
  • Local Institution
    Linkoping, 581 85, Sweden
  • Local Institution
    Malmo, 205 02, Sweden
  • Local Institution
    Stockholm, 171 76, Sweden
  • Local Institution
    Uppsala, 751 85, Sweden
09

References and documents

Publications

  • Ahmad HA, Baker JF, Conaghan PG, Emery P, Huizinga TWJ, Elbez Y, Banerjee S, Ostergaard M. Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. Arthritis Res Ther. 2022 Feb 16;24(1):47. doi: 10.1186/s13075-022-02735-8. PubMed 35172859 ↗
  • Keystone EC, Ahmad HA, Yazici Y, Bergman MJ. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology (Oxford). 2020 Aug 1;59(8):2090-2098. doi: 10.1093/rheumatology/kez455. PubMed 31819995 ↗
  • Ahmad HA, Baker JF, Ostergaard M, Ye J, Emery P, Conaghan PG. Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial. Adv Ther. 2019 Sep;36(9):2384-2393. doi: 10.1007/s12325-019-01020-6. Epub 2019 Jul 5. PubMed 31278695 ↗
  • Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW. Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019. PubMed 30997151 ↗
  • Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum In: Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9. PubMed 30341453 ↗
  • Peterfy C, Burmester GR, Bykerk VP, Combe BG, DiCarlo JC, Furst DE, Huizinga TW, Wong DA, Conaghan PG, Emery P. Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Ann Rheum Dis. 2016 Aug;75(8):1501-5. doi: 10.1136/annrheumdis-2015-208258. Epub 2016 Feb 10. PubMed 26865601 ↗
  • Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, Karyekar CS, Wong DA, Huizinga TW. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 Jan;74(1):19-26. doi: 10.1136/annrheumdis-2014-206106. Epub 2014 Nov 3. PubMed 25367713 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Sep 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2010
First posted
Jun 11, 2010
Start
Dec 2010
Primary completionActual
Sep 2013
CompletionActual
Oct 2014
Results first posted
Oct 17, 2014
Last update
Jan 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01142726
Responsible party
Sponsor
First posted
Jun 11, 2010
Start date
Dec 2010
Primary completion
Sep 2013
Completion
Oct 2014
Results posted
Oct 17, 2014
Last update
Jan 14, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abatacept · Methotrexate

Start the discussion